吡柔比星早期灌注治疗预防膀胱癌复发的疗效观察被引量：6

Effect on prophase intravesical instillation of pirarubicin for preventing recurrence of bladder cancer

下载PDF

导出

摘要目的评估经尿道膀胱肿瘤电切(TURBT)术后吡柔比星早期膀胱灌注预防膀胱癌复发的疗效。方法选取90例膀胱癌患者,随机分为早期灌注组(A组,n=45)和常规维持灌注组(B组,n=45)。A组于TURBT术后6 h行吡柔比星30 mg膀胱内灌注,术后1周两组均行吡柔比星常规灌注化疗,比较两组膀胱癌的复发率。结果 A、B两组膀胱癌的复发率分别为6.7%和17.8%,组间差异有统计学意义(P<0.05)。两组均未出现严重不良反应。结论 TUBBT术后吡柔比星早期灌注化疗能降低膀胱癌复发,疗效确切且安全耐受。 Objective To evaluate the effect on prophase intravesical instillation of pirarubicin for preventing from recurrence of bladder cancer after transurethral bladder tumor resection（TURBT）.Methods Ninety cases of bladder cancer patients were randomly divided into prophase instillation group（group A,n=45） and routine instillation group（group B,n=45）.Group A accepted intravesical instillation of pirarubicin 30 mg within 6 h after operation.Then two groups started routine treatment of pirarubicin after one week of operation.The recurrence rates were compared between two groups.Results The recurrence rates of group A and B were 6.7% and 17.8%,and there was significant difference between two groups（P0.05）.No severe adverse reactions in two groups were observed.Conclusion The recurrence rate of bladder cancer may reduce by prophase intravesical instillation of pirarubicin after TURBT.It is effective and safe.

作者沈俭陈建华俞奇伟沈杰孙鹏

机构地区上海交通大学医学院附属新华医院崇明分院泌尿外科上海交通大学医学院附属新华医院泌尿外科

出处《世界临床药物》 CAS 2011年第5期284-286,共3页 World Clinical Drug

关键词吡柔比星膀胱癌灌注复发不良反应 pirarubicin bladder cancer instillation recurrence adverse reaction

分类号 R979.1 [医药卫生—药品] R737.14 [医药卫生—肿瘤]

引文网络
相关文献

参考文献7

1Kaufman DS,Shipley WU,Feldman AS.Bladder cancer[J].Lancet,2009,374(9685):239-249.
2Jemal A,Murray T,Ward E,et al.Cancer statistics,2005[J].CA Cancer J Clin,2005,55(1):10-30.
3Knowles MA.Bladder cancer subtypes defined by genomic alterations[J].Stand J Urol Nephrol Suppl,2008(218):116-130.
4Mak RH,zl Etman AL,Heney NM,et al.Bladder preservation optimizing radiotherapy and integrated treatment strategies[J].BJU Int,2008,102(9):1345-1353.
5Maruyama T,Higuchi Y,Suzuki T,et al.Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells[J].J Infect Chemother,2011,17(1):11-16.
6李清,徐涛,王晓峰.吡柔比星膀胱内灌注预防非肌层浸润性膀胱尿路上皮癌复发的机制[J].中华肿瘤杂志,2009,31(12):904-907. 被引量：29
7Kobayashi S,Oka K,Machida T,et al.5 years intravesical instillation with mitomycin-C and pirarubicin as a prophylactic treatment for superficial bladder cancer[J].Nippon Hinyokika Gakkai Zasshi,2006,97(4):636-641.

二级参考文献12

1Waters WB. Invasive bladder cancer: where do we go from here? J Urol, 1996, 155:1910-1911.
2Tolley DA, Parrrkar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol, 1996, 155 : 1233-1238.
3Sylvester RJ, van der Meijden AP, Osterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006, 49:466- 477.
4Okamura K, Ono Y, Kinukawa S, et al. Randomized study of single early instillation of ( 2" R )4'-O-tetrahydropyranyl- doxorubicin for a single superficial bladder carcinoma. Cancer, 2002, 94:2363-2368.
5Akaza H, Kurth KH, Williams R, et al. Intravesical chemotherapy and immunotherapy for superficial tumour: Basic mechanism of action and future direction. Urol Oncol, 1998, 4 : 121-129.
6Gasion JP, Cruz JF. Improving efficacy of intravesical chemotherapy. Eur Urol, 2006, 50:225-234.
7Sonpavde G, Petrylak DP. Perioperative chemotherapy for bladder cancer. Crit Rev Oncol Hematol, 2006, 57:133-144.
8Takahashi T, Kushiro A, Nomoto K, et al. Antitumor effects of the intravesical instillation of heat killed cells of the Lactobacillus casei strain Shirota on the murine orthotopic bladder tumor MBT- 2. J Urol, 2001, 166:2506-2511.
9Iguchi H, Teranishi Y, Tone 14 Vesical tissue concentration of pirarubicin after intravesical instillation in rats. Basic Clin Report, 1994, 28: 21-24.
10Yamamoto Y, Nasu Y, Saika T, et al. The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. BJU Int, 2000, 86 : 802-804.